News in COVID-19

The BNT162b2 mRNA vaccine has a similar profile of short-term side effects for cancer patients undergoing immune checkpoint inhibitor therapy and healthy individuals

Changes were made in the delivery of radical radiotherapy across the UK in response to COVID-19 adapted guidelines

Changes were made in the delivery of radical radiotherapy across the UK in response to COVID-19 adapted guidelines

More patients diagnosed with stage IV non-small cell lung cancer presented with brain metastases compared to historic rates

More patients diagnosed with stage IV non-small cell lung cancer presented with brain metastases compared to historic rates

A deep-learning algorithm can help to discriminate radiation pneumonitis from COVID-19 pneumonia

A deep-learning algorithm can help to discriminate radiation pneumonitis from COVID-19 pneumonia

Findings from the COVID-19 and Cancer Consortium

Results from a cross-sectional survey in France

Use of radiotherapy changed significantly in England during the first COVID-19 wave

Use of systemic treatments by cancer patients in England fell in April 2020 but surged in June 2020

Dutch registry findings describe the effect of the SARS-CoV-2 pandemic on cancer patients and the general population

Systemic inflammation is a key driver of mortality in SARS-CoV-2 in cancer patients and biomarkers of inflamation may be used to identify patients at increased risk

Systemic inflammation is a key driver of mortality in SARS-CoV-2 in cancer patients and biomarkers of inflamation may be used to identify patients at increased risk

IgG antibody response to SARS-CoV-2 infection may be comparable among cancer patients and healthy oncology healthcare workers

IgG antibody response to SARS-CoV-2 infection may be comparable among cancer patients and healthy oncology healthcare workers

Interim results of the SAKK 80/20 CaSA study suggest around 18% of Swiss cancer patients with SARS-CoV-2 infection have died

Interim results of the SAKK 80/20 CaSA study suggest around 18% of Swiss cancer patients with SARS-CoV-2 infection have died

Online surveys have revealed the impact of the COVID-19 pandemic on the wellbeing of oncology professionals

Online surveys have revealed the impact of the COVID-19 pandemic on the wellbeing of oncology professionals

Literature analysis suggests that approximately 25% of cancer patients with COVID-19 have died

Low SARS-CoV-2 seroprevalence in both, oncology healthcare workers and cancer patients require continuation of strict safety measures

ESMO has taken the decision due to the uncertain evolution of the Coronavirus pandemic in the Asia-Pacific region and to avoid any risks to the health of the Faculty, delegates and staff.

UK data suggest the risk of acquiring COVID-19 and the severity of infection differ by the type of cancer

Findings from a systematic review and meta-analysis

Haematological malignancy patients with COVID-19 may have a high mortality rate

Findings from a large regional analysis of population that examined the prevalence of cancer and clinical outcomes of viral infection

Findings from a large testing study conducted at a tertiary care hospital in Vienna

An experience of the Drug Development Department of the Gustave Roussy

Restrictive measures to control the spread of COVID-19 have adverse effect on continuation of radiotherapy in patients with cancer

In Annals of Oncology, ESMO’s comprehensive set of recommendations address open questions on how to manage cancer care in the COVID-19 era

Modelling studies predict the outcome of COVID-19 pandemic-related cancer diagnostic delays in England

An interim analysis of survey data in the context of the COVID-19 pandemic

Data from prostate cancer patients in Italy and Finland do not support the hypothesis that androgen deprivation therapy may reduce the risk of SARS-CoV-2 infection

Results from the survey among 5302 cancer patients in the Netherlands

A delay in cancer surgery because of the COVID-19 pandemic may have a significant impact on patient survival

An immunocompromised cancer patient with bone marrow positive for SARS-CoV-2 has developed pancytopenia

A study of cancer patients attending a New York hospital details the rates of hospitalisation, morbidity and mortality associated with COVID-19

Around 10% of cancer patients with suspected or confirmed COVID-19 die within 25 days of being admitted to hospital with symptoms

A study of cancer patients with COVID-19 has identified several risk factors for mortality

More safety data is needed in terms of treatment of symptomatic COVID-19 patients with anticancer drugs

Findings from the MSKCC series

Findings from two Chinese multicentre, retrospective, cohort studies

Results of the UK Coronavirus Cancer Monitoring Project 

The TERAVOLT consortium has identified patient- and treatment-related factors associated with an increased risk for death among thoracic cancer patients with COVID-19 infection

Cancer patients with COVID-19 have specific risk factors that may help contribute to a high rate of mortality

Multifactorial reasons involving patients, general practitioners and the healthcare system

Prostate cancer patients using androgen deprivation therapy might have a lower risk of SARS-CoV-2 infection than other cancer patients